10 Years

Back in December 2007 I was browsing the job classifieds in the local paper and came across an ad for an administration officer for the Myeloma Foundation of Australia Inc. I started at the end of Jan...

BLOOD

A team from Myeloma Australia had the opportunity to attend ‘Blood2018’ (formerly HAA) the largest haematology conference in Australia in Brisbane at the end of October. With our team of ten Myeloma S...

PBS listing changes for Pomalidomide – through the eyes of a Myeloma Support Nurse:

Just over two weeks ago, we were delighted to hear at Myeloma Australia the changes to the pharmaceutical benefit scheme (PBS) listing for Pomalidomide (Pomalyst®). Whilst the notation was slight, the...

Sydney City2Surf Running Blog

Running blog “Let the training commence” “White rabbits” “pinch, punch first day of the month” also day one of my training for “Team Myeloma” City to Surf 2018! I have entered this event several times...

PBAC consumer comments open for denosumab

Myeloma Australia is committed to keeping the Australian myeloma community informed about any new treatment submissions to be considered by the Pharmaceutical Benefits Advisory Committee (PBAC). The P...

0

American Society of Hematology Meeting 2017

A team from Myeloma Australia visited Atlanta USA in December 2017 as invited guests of the International Myeloma Foundation (IMF). This gave us the opportunity to attend the world’s biggest haematolo...

Updates from the Pharmaceutical Benefits Advisory Committee (PBAC) 22 Dec 2017

The PBAC met in November this year to review the most recent applications for new drugs or amendments to the prescribing rules for existing drugs. Four myeloma drugs were reviewed during this meeting....

Welcome to our new website!

From our first guest blogger, CEO Steve Roach   Hello and welcome to our first blog. We hope this part of our website will allow us to be interactive, informative, helpful and maybe even humorous...